What is the appropriate management for a woman with pulsatile tinnitus in the right ear that occurs during heavy menstrual bleeding or when hemoglobin falls below 10 g/dL, who cannot take oral ferrous iron because of gastritis and has previously reacted to intravenous iron dextran?

Management Recommendation

This patient should receive an alternative intravenous iron formulation—specifically ferric decarboxymaltose (FDI), ferumoxytol, or iron sucrose—to correct her iron deficiency anemia, which is the underlying cause of her pulsatile tinnitus. 1, 2

Rationale for IV Iron Therapy

Your patient's pulsatile tinnitus is directly linked to her anemia and iron deficiency, as evidenced by symptom onset when hemoglobin drops below 10 g/dL. Recent cohort data demonstrates that iron deficiency anemia significantly increases the risk of new-onset tinnitus in women (HR 3.78 at 1 year, HR 2.52 at 3 years), with a clear dose-response relationship where severe anemia (Hgb <10 g/dL) confers the highest risk 3. The mechanism involves cochlear hypoxia and altered hemodynamics from anemia.

Intravenous iron is absolutely indicated because she cannot tolerate oral iron due to gastritis and has had a reaction to iron dextran 2, 4. The 2024 AGA guidelines explicitly state that IV iron should be used when patients do not tolerate oral iron 2.

Specific IV Iron Formulation Selection

Avoid Iron Dextran

Do not retry any iron dextran formulation. The FDA label warns of anaphylactic-type reactions including fatalities, and notes that "fatal reactions have followed the test dose of iron dextran and have also occurred in situations where the test dose was tolerated" 4. Her prior reaction is an absolute contraindication.

Recommended Alternatives (in order of preference):

1. Ferric Decarboxymaltose (FDI) - First choice

   • Can deliver 1000 mg in a single infusion (or up to 1500 mg based on weight)
   • Only formulation FDA-approved for total dose infusion
   • Dilute in 100 mL normal saline
   • Has demonstrated cardiovascular mortality benefit in heart failure patients
   • Equally safe and efficacious compared to other modern formulations 1

2. Ferumoxytol - Second choice

   • Can deliver 510 mg per infusion (typically two infusions needed)
   • Similar safety profile to FDI 1

3. Iron Sucrose or Ferric Gluconate - Third choice

   • Require multiple infusions (typically >2 doses)
   • Less convenient but well-established safety profiles 1, 2

The 2024 expert consensus guidelines specifically recommend formulations requiring 1-2 infusions over those requiring more than 2 infusions 2.

Important Safety Considerations

All IV iron formulations carry similar overall risks, and true anaphylaxis is very rare 2. The vast majority of reactions are complement activation-related pseudo-allergy (CARP), not true anaphylaxis. These infusion reactions should be managed as such—they are not contraindications to future use of different formulations.

Critical Pitfall to Avoid

Do not assume cross-reactivity between iron dextran and other IV iron formulations. The 2024 guidelines emphasize that "iron dextran products differ in chemical characteristics and may differ in clinical effects. Iron dextran products are not clinically interchangeable" 1. Modern formulations like FDI, ferumoxytol, and iron sucrose have completely different carbohydrate shells and do not share the same allergenic properties as iron dextran.

Administration Protocol

• Ensure resuscitation equipment and trained personnel are available during infusion
• Monitor patient for at least 1 hour after infusion
• For FDI: 1000 mg in 100 mL normal saline as single infusion 1

Addressing the Heavy Menstrual Bleeding

While correcting the iron deficiency, simultaneously evaluate and treat the underlying heavy menstrual bleeding to prevent recurrence. The frequency of IV iron administration depends on ongoing blood loss 1. With continued heavy menses, she will require repeated iron replacement.

Monitoring Response

• Check CBC 1-2 weeks after infusion (hemoglobin should increase by this time)
• Check CBC and iron parameters (ferritin, TSAT) at 4-8 weeks post-infusion
• Do not check iron parameters within 4 weeks of total dose infusion—circulating iron interferes with assays leading to spurious results 1
• Target ferritin ≥50 ng/mL in absence of inflammation
• TSAT <20% indicates ongoing iron deficiency 1

Expected Outcome for Pulsatile Tinnitus

Correcting her anemia should resolve the pulsatile tinnitus, as the symptom is clearly hemoglobin-dependent in her case. However, if pulsatile tinnitus persists after hemoglobin normalization, vascular imaging would be warranted to exclude structural vascular causes 5, 6.